

Date: 9<sup>th</sup> December, 2024

<b>BSE Limited</b> Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400 001  <b>Scrip Code: 539872</b>	<b>National Stock Exchange of India Limited</b> 5 <sup>th</sup> Floor, Exchange Plaza, Bandra Kurla Complex Bandra (East) Mumbai-400051  <b>Symbol: BAJAJHCARE</b>
--	---

Dear Sir/Madam,

**Subject: Intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015 about Bajaj Healthcare Limited (“the Company”) entering into a CDMO Contract with UK/ EU based Companies**

We are pleased to inform the exchanges about the Company entering into a definitive CDMO contract with UK/EU based companies for 15 new APIs. This is in addition to 15 molecules for which we entered the contract with UK/EU based clients on 27<sup>th</sup> February 2024. The new CDMO pipeline has a mix of, off Patent Generic APIs as well as APIs which are still under patent.

Speaking at the occasion Mr. Anil Jain, Managing Director, Bajaj Healthcare Limited, said “We are delighted to share this development which reinforces the capabilities that we are building in terms of cost-effective route of synthesis in our R&D and the expansion of manufacturing capabilities, mostly at our USFDA, EU and now TGA, Australia approved site located at Block No. 588, Savli-Karachiya Road, At & Post: Gothada, Tal. Savli, Dist: Vadodara, Gujarat. The company is likely to enter into few CDMO deals with clients in Australia, New Zealand and South Africa, after the approval of the site by the TGA.

Kindly take the same on record.

Thanking You,

**For and Behalf of Board of Director of  
Bajaj Healthcare Limited**

**Apurva Bandivadekar  
Company Secretary & Compliance Officer**